VERA - NASDAQ
Vera Therapeutics, Inc.
$32.75
+4.7%Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
At a Glance
Live Snapshotvera
Cash at Beginning of Period
Last Annual Value
92.65M
3-Year CAGR
5%
5-Year CAGR
92%
10-Year CAGR
21%
Vera Therapeutics, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Vera Therapeutics, Inc. NASDAQ:VERA | 92.65M | 28.4% | 11.4% | N/A | |
 Nuvation Bio Inc. NYSE:NUVB | 35.72M | -29.3% | 3.7% | N/A | |
 uniQure N.V. NASDAQ:QURE | 158.93M | -11.7% | -8.5% | -3.3% | |
 Janux Therapeutics, Inc. NASDAQ:JANX | 431.42M | 102.1% | 123.1% | N/A | |
 Immunome, Inc. NASDAQ:IMNM | 143.45M | 91.5% | 29.2% | N/A | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 28.36M | -1.2% | -8.3% | -8.9% | |
 Biohaven Ltd. NYSE:BHVN | 102.54M | -25.0% | 4.2% | N/A | |
 Harmony Biosciences Holdings, Inc. NASDAQ:HRMY | 453.00M | 22.8% | 14.6% | N/A | |
 Viridian Therapeutics, Inc. NASDAQ:VRDN | 99.59M | -13.8% | 16.8% | 24.8% |
Vera Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your VERA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.